Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.

Journal Information

Full Title: Ann Surg Oncol

Abbreviation: Ann Surg Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: General Surgery

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosures C.J.P.: Nordic Pharma. E.W.: None. F.v.d.B.: None. G.V.: BMS, Merck, Servier, Personal Genome Diagnostics, Bayer, Sirtex, Pierre Fabre, Lilly. I.d.H.: ROCHE, RanD Biotech. J.H.: None. J.R.: Bayer, BMS, Merck-Serono, Pierre Fabre, Servier, HUB4organoids, Cleara Biotech. K.B.: None. K.Z.: None. M.K.: Nordic Farma, Merck-Serono, Pierre Fabre, Servier, Bayer, Bristol Myers Squibb, Merck, Roche and Servier. M.L.: None. W.v.G.: None."

Evidence found in paper:

"Funding No funder or sponsor was involved in this study."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025